STO · BRAIN.ST
BrainCool AB (publ)
SEK 1.03-SEK 0.04 (-3.37%)
BrainCool AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 10.26% below the high.
Loading market information…
STO · KLAR.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:24 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Klaria Pharma Holding AB (publ.)’s quoted price sits in the lower half of its reported 52-week range, 60.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Klaria Pharma Holding AB (publ.)’s next earnings report is currently expected on Nov 26, 2026, with estimated earnings per share of SEK 0.22. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Klaria Pharma Holding AB (publ.)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 28, 2025 |
| -SEK 0.11 |
| SEK 1.07M |
| Q3 2024 | Nov 21, 2024 | -SEK 0.06 | SEK 0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.03-SEK 0.04 (-3.37%)
BrainCool AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 10.26% below the high.
SEK 1.19+SEK 0.04 (+3.66%)
Isofol Medical AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.96% below the high.
SEK 8.34-SEK 0.08 (-0.95%)
Integrum AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 30.15% below the high.
SEK 13.00-SEK 2.85 (-17.98%)
Xbrane Biopharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.0% below the high.
SEK 12.65-SEK 0.40 (-3.07%)
SciBase Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.57% below the high.
SEK 0.38+SEK 0.00 (+1.08%)
Alzinova AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 81.86% below the high.
SEK 14.70-SEK 0.30 (-2.0%)
Q-linea AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 61.74% below the high.
SEK 0.40-SEK 0.01 (-2.69%)
AcuCort AB’s quoted price sits in the lower half of its reported 52-week range, 58.11% below the high.
